Table 4.
Treatment | Dose (mg/kg) |
Carrageenan-induced leukocyte migration (leukocytes ×106/mL)a | % inhibition | Carrageenan-induced hindpaw edema volume (mL)a | % inhibition |
---|---|---|---|---|---|
Vehicle | — | 48.3 ± 2.8 | — | 0.61 ± 0.14 | — |
EOX | 12.5 | 32.1 ± 3.6b | 33.5d | 0.40 ± 0.11b | 34.4d |
EOX | 25 | 30.7 ± 2.2b | 36.4d | 0.36 ± 0.09b | 41.0d |
EOX | 50 | 27.8 ± 4.3c | 42.4d | 0.34 ± 0.11b | 44.3d |
INDO | 10 | 19.7 ± 2.5c | 59.2e | 0.21 ± 0.08c | 65.6e |
n = 6, per group. aValues represent mean ± S.E.M. b P < 0.01 (one-way ANOVA and Tukey's test), significantly different from control. c P < 0.001 (one-way ANOVA and Tukey's test), significantly different from control. d P < 0.01 (Fisher's test), significantly different from control. e P < 0.001 (Fisher's test), significantly different from control.